In Vivo Efficacy of the Ketolide ABT-773 (Cethromycin) against Enterococci in a Mouse Peritonitis Model

AUTOR(ES)

Pai, Suresh R.

FONTE

American Society for Microbiology

RESUMO

Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

Documentos Relacionados

• Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro
• In Vitro Activity of the Ketolide ABT-773
• Activity of ABT-773 against Mycobacterium avium Complex in the Beige Mouse Model
• Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model
• Activities of ABT-773 against Microaerophilic and Fastidious Organisms